FDA Mandates Vision Loss Warnings for GLP-1 Weight Loss Drugs
Regulators require label updates for Ozempic, Wegovy, and Mounjaro due to optic nerve risks.
1Regulatory Action on GLP-1
The US Food and Drug Administration has officially mandated that manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, update their product labels. These new warnings must explicitly address the potential risk of a serious eye condition known as NAION, which can lead to permanent vision loss for some patients.
2Understanding NAION Risks
NAION, or non-arteritic anterior ischemic optic neuropathy, occurs when blood flow to the optic nerve is significantly reduced. This condition can result in sudden, irreversible vision impairment. The FDA decision follows a comprehensive review of clinical trial data, animal studies, and post-market reports collected from patients using these popular weight-loss medications.
3Manufacturer Responses to Mandate
Eli Lilly, the producer of Mounjaro and Zepbound, stated they are reviewing the FDA update carefully and will respond promptly, noting no specific findings were cited. Novo Nordisk, the maker of Ozempic and Wegovy, maintains that current data does not establish a direct cause-and-effect relationship, expressing continued confidence in their products' safety profiles.
4European Safety Committee Findings
In 2025, the European Medicines Agency's safety committee identified that NAION could potentially affect one in every 10,000 users of semaglutide who have been on the medication for at least one year. This marked the first time a major regulatory body officially confirmed the occurrence of this specific side effect in clinical settings.
5Evidence from Clinical Studies
A large-scale study published in 2025 analyzed approximately 175,000 diabetic patients treated with semaglutide against a control group using different medication classes. The research revealed that the risk of developing NAION more than doubled after two years of treatment with GLP-1 based drugs, providing a statistical basis for the new regulatory warnings.
6Legal and Compensation Precedents
The issue has already moved beyond clinical warnings into the legal sphere. In Denmark, four patients who experienced vision loss after using weight-loss pens manufactured by Novo Nordisk have successfully received financial compensation. These cases highlight the growing scrutiny regarding the long-term ocular safety of these widely prescribed metabolic health treatments.
7Scope of Affected Medications
The FDA directive applies broadly to the class of GLP-1 agonists, which are currently experiencing high global demand for obesity and diabetes management. By requiring these label changes, the agency aims to ensure that both healthcare providers and patients are fully informed about the potential for optic nerve damage before initiating long-term therapy.
8Future Clinical Monitoring Needs
As these drugs continue to be prescribed to millions, the focus now shifts to how physicians will monitor ocular health in patients. The FDA mandate serves as a critical reminder of the importance of post-market surveillance. Patients should remain vigilant for sudden vision changes and consult their doctors immediately if symptoms arise during treatment.
Original article: Folha de S.Paulo — FDA Mandates Vision Loss Warnings for GLP-1 Weight Loss Drugs